#USA #New York #Levi & Korsinsky #Securities Class Action #Regeneron Pharmaceuticals

Class Action Alert for Regeneron Pharmaceuticals Investors

Levi & Korsinsky, LLP has recently issued a notice to institutional investors regarding an emerging class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This lawsuit stems from claims that Regeneron provided misleading information related to its clinical trial disclosures. The timeline of allegations stretches from August 1, 2025, to May 15, 2026, and those who purchased shares within this period may be eligible to recover significant losses.

Understanding the Case

The share price of Regeneron experienced a sharp decline, falling from $731.77 on April 28, 2026, to $629.68 by May 15, leading to an approximate loss of 14%. Recent disclosures indicated that the company's Phase III clinical trial related to its drug Fianlimab-Libtayo may not have fulfilled its primary endpoint, raising questions about the reliability of the information that was previously shared with investors. This has further fueled investor concerns and will likely affect the fiduciary responsibilities of many institutional holders.

Fiduciary Responsibilities and Legal Recourse

Institutional investors are advised to evaluate their investment strategies regarding Regeneron shares amid this ongoing legal issue. Key factors to consider include:

• - Documentation: Maintaining records of purchases and sales of REGN stock, especially between August 1, 2025, and May 15, 2026.
• - Governance: Reflection on fiduciary obligations concerning oversight of investments and loss documentation.
• - Potential Recovery: An assessment of whether the losses incurred during this class action period warrant pursuing recovery.

The focus of the lawsuit revolves around claims that Regeneron failed to adequately disclose the risks associated with the clinical trials, which could have materially affected the trading price of their shares. As such, it is crucial for investors to preserve any related documents, such as brokerage statements and trade confirmations that detail purchase dates and quantities.

Key Considerations for Investors

Levi & Korsinsky emphasizes the importance of identifying whether institutional holders may qualify for a lead plaintiff role. This designation is granted to an investor with the largest verifiable losses that steps up to guide the collective interests of all affected shareholders. While being a lead plaintiff does not increase individual recoveries, it does allow for direct oversight of the case management, which can be of significant importance in a class action.

Individuals who feel they may qualify to participate in the lawsuit are encouraged to act quickly, as the lead plaintiff deadline is set for September 14, 2026.

Frequently Asked Questions

Q: How can I determine if I'm eligible to join this lawsuit?
A: Eligibility primarily involves whether you acquired REGN shares during the specified time frame and suffered financial losses as a result.

Q: What does the lawsuit claim?
A: The allegations suggest that Regeneron made materially false or misleading statements regarding the Phase III study, presenting overly optimistic results while downplaying associated risks and impacts on outcomes.

Q: Will participation in the lawsuit require direct court appearances?
A: Generally, class members are not required to appear in court or provide testimony. Most claims are handled through a claim form for eligible participants.

Contact Information

Investors interested in learning more about the lawsuit or assessing their involvement are encouraged to reach out to Levi & Korsinsky, LLP. Potential participants can get in touch with attorney Joseph E. Levi at (212) 363-7500.

Levi & Korsinsky, LLP continues to serve institutional investors in recovering losses and ensuring compliance with fiduciary duties.